Vanessa Damazio Teich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vanessa Damazio Teich has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Cendoroglo
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
7 shared publications - Daniel Tavares Malheiro
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
6 shared publications - Adriana Serra Cypriano
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
4 shared publications - Claudia Regina Laselva
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
4 shared publications - Sidney Klajner
Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
4 shared publications - Bruno de Arruda Bravim
Affiliation Intensive Care Unit – Hospital Israelita Albert Einstein, São Paulo, Brazil
3 shared publications
Latest Publications
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500501
From Diagnosis to Execution: A National Plan Proposal to Redesign Clinical Research in Brazil to Improve Cancer Care and Innovation Access
Brazil has substantial capacity to contribute to global clinical research, supported by its population size, epidemiological diversity, and the Unified Health System (SUS). Despite this potential, the country has been described in policy documents and stakeholder discussions as being underrepresented in international clinical trials, reflecting persistent regulatory, operational, and structural barriers. Law No. 14.874/2024 was discussed as representing a major regulatory milestone, although its impact depends on effective implementation and system-level coordination. This article is based on a structured, multistakeholder deliberative process conducted during the First Annual Clinical Research Meeting (Encontro Anual de pesquisa Clinica — in Brazilian Portuguese), held in Brazil in May 2025. The meeting convened 20 speakers from industry, research organizations, clinical investigators, public and private research centers, patient advocacy groups, civil society, and health policy. Discussions were organized through plenary sessions and thematic working groups. A qualitative synthesis was conducted after the meeting to identify convergent policy directions and areas of divergence. Key challenges identified during the deliberative process included regulatory predictability, taxation and importation of research supplies, mandatory post-trial access, underutilization of SUS, workforce constraints, logistical bottlenecks, regional inequities, and limited public trust. Convergent policy directions discussed by participants emphasized effective secondary regulation of Law No. 14.874/2024, digital transformation, stronger integration of clinical research within SUS, workforce professionalization, patient-centered trial designs, and differentiated approaches for rare diseases and priority populations. Strengthening Brazil's clinical research ecosystem was described by participants as requiring coordinated policy action, transparent governance, and sustained investment. The policy directions synthesized here, derived from multistakeholder deliberation, are intended to inform regulatory development and institutional strategies rather than to serve as a formal consensus statement or implementation plan.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500501
From Diagnosis to Execution: A National Plan Proposal to Redesign Clinical Research in Brazil to Improve Cancer Care and Innovation Access
Brazil has substantial capacity to contribute to global clinical research, supported by its population size, epidemiological diversity, and the Unified Health System (SUS). Despite this potential, the country has been described in policy documents and stakeholder discussions as being underrepresented in international clinical trials, reflecting persistent regulatory, operational, and structural barriers. Law No. 14.874/2024 was discussed as representing a major regulatory milestone, although its impact depends on effective implementation and system-level coordination. This article is based on a structured, multistakeholder deliberative process conducted during the First Annual Clinical Research Meeting (Encontro Anual de pesquisa Clinica — in Brazilian Portuguese), held in Brazil in May 2025. The meeting convened 20 speakers from industry, research organizations, clinical investigators, public and private research centers, patient advocacy groups, civil society, and health policy. Discussions were organized through plenary sessions and thematic working groups. A qualitative synthesis was conducted after the meeting to identify convergent policy directions and areas of divergence. Key challenges identified during the deliberative process included regulatory predictability, taxation and importation of research supplies, mandatory post-trial access, underutilization of SUS, workforce constraints, logistical bottlenecks, regional inequities, and limited public trust. Convergent policy directions discussed by participants emphasized effective secondary regulation of Law No. 14.874/2024, digital transformation, stronger integration of clinical research within SUS, workforce professionalization, patient-centered trial designs, and differentiated approaches for rare diseases and priority populations. Strengthening Brazil's clinical research ecosystem was described by participants as requiring coordinated policy action, transparent governance, and sustained investment. The policy directions synthesized here, derived from multistakeholder deliberation, are intended to inform regulatory development and institutional strategies rather than to serve as a formal consensus statement or implementation plan.
- Open Access
- 11 March 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24 (spe2) , eAO1834
Cost of hematopoietic cell transplantation for hematologic malignancies from a transplant center in a developing country
Highlights ■ Costs compared across matched sibling donor, unrelated donor, and Haplo transplants. ■ A total of 177 patients with hematologic malignancies were analyzed. ■ Matched sibling donor transplants had the lowest 1-year costs. ■ Unrelated donor and Haplo transplants were significantly more expensive than matched sibling donor. ABSTRACT Objective: Hematopoietic cell transplantation is a resource-intensive procedure influenced by several cost drivers. The primary objective of this study was to compare the costs of matched-sibling (MSD), unrelated (URD), and haploidentical
- 11 March 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24 (spe2) , eAO1834
Open AccessCost of hematopoietic cell transplantation for hematologic malignancies from a transplant center in a developing country
Highlights ■ Costs compared across matched sibling donor, unrelated donor, and Haplo transplants. ■ A total of 177 patients with hematologic malignancies were analyzed. ■ Matched sibling donor transplants had the lowest 1-year costs. ■ Unrelated donor and Haplo transplants were significantly more expensive than matched sibling donor. ABSTRACT Objective: Hematopoietic cell transplantation is a resource-intensive procedure influenced by several cost drivers. The primary objective of this study was to compare the costs of matched-sibling (MSD), unrelated (URD), and haploidentical
- Open Access
- 11 September 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eGS1301
Judicial demands for prostate cancer treatment in Brazil: androgen receptor pathway inhibitors are an urgent public health problem
Highlights ■ A total of 89% of the 3,136 legal demands sought medication. ■ Androgen inhibitors amounted to 78.8% of all lawsuits, particularly abiraterone. ■ There is a growth tendency in judicialization, with a 30-fold increase over 4 years. ■ The estimated annual financial burden of judicialization on the Brazilian United Public Health System has reached BRL 783 million. ABSTRACT Objective: Considering the difficulties of Brazil’s Public Health System in providing comprehensive care, the present article aimed to assess legal
- 11 September 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eGS1301
Open AccessJudicial demands for prostate cancer treatment in Brazil: androgen receptor pathway inhibitors are an urgent public health problem
Highlights ■ A total of 89% of the 3,136 legal demands sought medication. ■ Androgen inhibitors amounted to 78.8% of all lawsuits, particularly abiraterone. ■ There is a growth tendency in judicialization, with a 30-fold increase over 4 years. ■ The estimated annual financial burden of judicialization on the Brazilian United Public Health System has reached BRL 783 million. ABSTRACT Objective: Considering the difficulties of Brazil’s Public Health System in providing comprehensive care, the present article aimed to assess legal
- Open Access
- 15 July 2025
- Published by Elsevier in Measurement and Evaluations in Cancer Care
- Vol. 3
Machine learning models for predicting surgical intervention in colorectal cancer
- 15 July 2025
- Published by Elsevier in Measurement and Evaluations in Cancer Care
- Vol. 3
Open AccessMachine learning models for predicting surgical intervention in colorectal cancer
- Open Access
- 26 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0939
Risk factors for healthcare-associated infections and their relationship with waves of the COVID-19 pandemic in an intensive care unit: a nested case-control study
Highlights Healthcare-associated infections are responsible for higher morbidity and mortality rates. The COVID-19 pandemic brought a scenario of enormous demand for healthcare. Knowledge of risk factors is important for preventive measures. COVID-19 and the length of hospital stay were the most important risk factors for healthcare-associated infections. ABSTRACT Objective: To evaluate the risk factors for healthcare-related infections during the COVID-19 pandemic in intensive care units, to investigate the impact of COVID-19 on Central Line- Associated Bloodstream Infection, Catheter-Associated Urinary Tract
- 26 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0939
Open AccessRisk factors for healthcare-associated infections and their relationship with waves of the COVID-19 pandemic in an intensive care unit: a nested case-control study
Highlights Healthcare-associated infections are responsible for higher morbidity and mortality rates. The COVID-19 pandemic brought a scenario of enormous demand for healthcare. Knowledge of risk factors is important for preventive measures. COVID-19 and the length of hospital stay were the most important risk factors for healthcare-associated infections. ABSTRACT Objective: To evaluate the risk factors for healthcare-related infections during the COVID-19 pandemic in intensive care units, to investigate the impact of COVID-19 on Central Line- Associated Bloodstream Infection, Catheter-Associated Urinary Tract
- Open Access
- 26 February 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0328
Is it possible to estimate the number of patients with COVID-19 admitted to intensive care units and general wards using clinical and telemedicine data?
Highlights Developed models to forecast bed occupancy for up to 14 days and monitored errors for 365 days. Telemedicine calls from COVID-19 patients correlated withthe number of patients hospitalized in the next 8 days. ABSTRACT Objective: To develop and validate predictive models to estimate the number of COVID-19 patients hospitalized in the intensive care units and general wards of a private not-for-profit hospital in São Paulo, Brazil. Methods: Two main models were developed. The first model calculated hospital occupation as
- 26 February 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0328
Open AccessIs it possible to estimate the number of patients with COVID-19 admitted to intensive care units and general wards using clinical and telemedicine data?
Highlights Developed models to forecast bed occupancy for up to 14 days and monitored errors for 365 days. Telemedicine calls from COVID-19 patients correlated withthe number of patients hospitalized in the next 8 days. ABSTRACT Objective: To develop and validate predictive models to estimate the number of COVID-19 patients hospitalized in the intensive care units and general wards of a private not-for-profit hospital in São Paulo, Brazil. Methods: Two main models were developed. The first model calculated hospital occupation as
- Open Access
- 14 February 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (2) , 212-214
Hemorrhagic code protocol, a successful case in the patient blood management model for patients with severe hemorrhages
- 14 February 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (2) , 212-214
Open AccessHemorrhagic code protocol, a successful case in the patient blood management model for patients with severe hemorrhages
- Open Access
- 5 July 2023
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21, eAO0233
Clinical characteristics and outcomes of patients with COVID-19 admitted to the intensive care unit during the first and second waves of the pandemic in Brazil: a single-center retrospective cohort study
Highlights We compared characteristics between patients admitted during the first and second waves. There were 1,427 intensive care unit patients with COVID-19: 421 (first wave) and 1,006 (second wave). The patients in the second wave were younger and less severely ill at the time of intensive care unit admission. Patients exhibited similar mortality rates and need for invasive organ support. ABSTRACT Objective To describe and compare the clinical characteristics and outcomes of patients admitted to intensive care units during the
- 5 July 2023
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21, eAO0233
Open AccessClinical characteristics and outcomes of patients with COVID-19 admitted to the intensive care unit during the first and second waves of the pandemic in Brazil: a single-center retrospective cohort study
Highlights We compared characteristics between patients admitted during the first and second waves. There were 1,427 intensive care unit patients with COVID-19: 421 (first wave) and 1,006 (second wave). The patients in the second wave were younger and less severely ill at the time of intensive care unit admission. Patients exhibited similar mortality rates and need for invasive organ support. ABSTRACT Objective To describe and compare the clinical characteristics and outcomes of patients admitted to intensive care units during the
- Open Access
- 22 June 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e104
Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil
Objective: To compare the long-term vaccine effectiveness between those receiving viral vector [Oxford-AstraZeneca (ChAdOx1)] or inactivated viral (CoronaVac) primary series (2 doses) and those who received an mRNA booster (Pfizer/BioNTech) (the third dose) among healthcare workers (HCWs).Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) in Brazil from January 2021 to July 2022. To assess the variation in the effectiveness of booster dose over time, we estimated the effectiveness rate by taking the log risk ratio as a function of time.Results: Of 14,532 HCWs, coronavirus disease 2019 (COVID-19) was confirmed in 56.3% of HCWs receiving 2 doses of CoronaVac vaccine versus 23.2% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster (P< .001), and 37.1% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 22.7% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster (P< .001). The highest vaccine effectiveness with mRNA booster was observed 30 days after vaccination: 91% for the CoronaVac vaccine group and 97% for the ChAdOx1 vaccine group. Vacine effectiveness declined to 55% and 67%, respectively, at 180 days. Of 430 samples screened for mutations, 49.5% were SARS-CoV-2 delta variants and 34.2% were SARS-CoV-2 omicron variants.Conclusions: Heterologous COVID-19 vaccines were effective for up to 180 days in preventing COVID-19 in the SARS-CoV-2 delta and omicron variant eras, which suggests the need for a second booster.
- 22 June 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e104
Open AccessLonger-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil
Objective: To compare the long-term vaccine effectiveness between those receiving viral vector [Oxford-AstraZeneca (ChAdOx1)] or inactivated viral (CoronaVac) primary series (2 doses) and those who received an mRNA booster (Pfizer/BioNTech) (the third dose) among healthcare workers (HCWs).Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) in Brazil from January 2021 to July 2022. To assess the variation in the effectiveness of booster dose over time, we estimated the effectiveness rate by taking the log risk ratio as a function of time.Results: Of 14,532 HCWs, coronavirus disease 2019 (COVID-19) was confirmed in 56.3% of HCWs receiving 2 doses of CoronaVac vaccine versus 23.2% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster (P< .001), and 37.1% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 22.7% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster (P< .001). The highest vaccine effectiveness with mRNA booster was observed 30 days after vaccination: 91% for the CoronaVac vaccine group and 97% for the ChAdOx1 vaccine group. Vacine effectiveness declined to 55% and 67%, respectively, at 180 days. Of 430 samples screened for mutations, 49.5% were SARS-CoV-2 delta variants and 34.2% were SARS-CoV-2 omicron variants.Conclusions: Heterologous COVID-19 vaccines were effective for up to 180 days in preventing COVID-19 in the SARS-CoV-2 delta and omicron variant eras, which suggests the need for a second booster.
- 29 September 2022
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 2 (1)
Adesão ao tratamento para esclerose múltipla com terapias de primeira linha: análise longitudinal retrospectiva
Objetivo: Avaliar os níveis de aderência e persistência de indivíduos com esclerose múltipla (EM) tratados com terapias de plataforma no Sistema Único de Saúde (SUS). Metodologia: Foi analisada uma coorte retrospectiva, onde a fonte de dados primária foi o DATASUS, utilizando as bases públicas disponíveis e anonimizadas. Para o mapeamento do indivíduo único foi feito um relacionamento determinístico a partir de informações disponíveis, que considera equivalentes os registros iguais em determinada chave. Foram incluídos os indivíduos: a) “naïve” ou recém diagnosticados com EM (CID10 G35); b) iniciando tratamento com: Avonexâ, Betaferonâ, Rebifâ ou Copaxoneâ; c) acompanhados por 13 a 18 meses (janeiro/2013 a setembro/2014). A aderência foi medida do pelo MPR (do inglês Medication Possession Ratio), onde MPR>0,8 foi considerada “aderente”. A persistência foi definida como o tempo em meses do início da terapia até o primeiro período >30 dias de espaço entre terapias. Resultados: O número total de indivíduos foi de 1.052, sendo Avonexâ (N=351, 33,4%); Betaferonâ (N=145, 13,8%); Copaxoneâ (N=264, 25,1%); e Rebifâ (N=292, 27,8%). O MPR>0.80 foi significativamente superior (p=0,0253) no grupo Avonexâ (71,8%) versus Betaferonâ (58,6%), Copaxoneâ (65,5%), e Rebifâ (63,7%). Não foram observadas diferenças significativas na persistência terapêutica entre as terapias. Discussão: Os resultados apresentados nesta análise longitudinal retrospectiva de indivíduos com EM tratados com terapias de primeira linha (plataforma) no SUS, condizem com aqueles identificados na literatura cientifica. Conclusão: De um ponto de vista da aderência e persistência terapêutica, Avonexâ mostra-se superior ou, no mínimo, equivalente às terapias de primeira linha no SUS.
- 29 September 2022
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 2 (1)
Adesão ao tratamento para esclerose múltipla com terapias de primeira linha: análise longitudinal retrospectiva
Objetivo: Avaliar os níveis de aderência e persistência de indivíduos com esclerose múltipla (EM) tratados com terapias de plataforma no Sistema Único de Saúde (SUS). Metodologia: Foi analisada uma coorte retrospectiva, onde a fonte de dados primária foi o DATASUS, utilizando as bases públicas disponíveis e anonimizadas. Para o mapeamento do indivíduo único foi feito um relacionamento determinístico a partir de informações disponíveis, que considera equivalentes os registros iguais em determinada chave. Foram incluídos os indivíduos: a) “naïve” ou recém diagnosticados com EM (CID10 G35); b) iniciando tratamento com: Avonexâ, Betaferonâ, Rebifâ ou Copaxoneâ; c) acompanhados por 13 a 18 meses (janeiro/2013 a setembro/2014). A aderência foi medida do pelo MPR (do inglês Medication Possession Ratio), onde MPR>0,8 foi considerada “aderente”. A persistência foi definida como o tempo em meses do início da terapia até o primeiro período >30 dias de espaço entre terapias. Resultados: O número total de indivíduos foi de 1.052, sendo Avonexâ (N=351, 33,4%); Betaferonâ (N=145, 13,8%); Copaxoneâ (N=264, 25,1%); e Rebifâ (N=292, 27,8%). O MPR>0.80 foi significativamente superior (p=0,0253) no grupo Avonexâ (71,8%) versus Betaferonâ (58,6%), Copaxoneâ (65,5%), e Rebifâ (63,7%). Não foram observadas diferenças significativas na persistência terapêutica entre as terapias. Discussão: Os resultados apresentados nesta análise longitudinal retrospectiva de indivíduos com EM tratados com terapias de primeira linha (plataforma) no SUS, condizem com aqueles identificados na literatura cientifica. Conclusão: De um ponto de vista da aderência e persistência terapêutica, Avonexâ mostra-se superior ou, no mínimo, equivalente às terapias de primeira linha no SUS.